RedHill Biopharma announces positive results of COVID-19 opaganib study

By Nikita Chaurasia  Date: 2021-01-05

RedHill Biopharma announces positive results of COVID-19 opaganib study

Israeli specialty biopharmaceutical company, RedHill Biopharma Ltd., has announced the preliminary data from the phase-2 clinical trials of its drug opaganib which was administered orally in patients suffering from COVID-19. The trial round included around 40 participants, with the study showing positive signals of efficacy and safety.

For the uninitiated, opaganib is an oral drug that acts as a sphingosine kinase-2 (SK2) inhibitor and is used for treating individuals with COVID-19 pneumonia. Its primary function is to target the host cell responsible for viral replication, thereby potentially minimizing the likelihood of viral resistance.

It is also worth mentioning that RedHill’s opaganib has received orphan drug designation by the U.S. Food & Drug Administration (FDA) for treating cholangiocarcinoma. The drug is currently being evaluated in a phase-2 study for the treatment of prostate cancer as well as cholangiocarcinoma.

If reports are to be believed, the preliminary data comes from a randomized, placebo-controlled, double-blind clinical trial round conducted on COVID-19 patients that required oxygen support. Furthermore, the trials found that there were no material safety differences between opaganib and the placebo treatment arms.

The drug reportedly demonstrated consistent progressive improvement in reducing oxygen requirements of the patients by the 14th day of the trial. Specifically, 52.6% of the patients in the opaganib group no longer required oxygen support as compared to 22.2% in the placebo group.

Medical director of RedHill Biopharma, Mark L. Levitt, was quoted saying that the organization expects the preliminary results from the recently conducted COVID-19 therapy study to support its global phase 2/3 study. The company will compile a robust data set for supporting the potential filing of emergency use applications, he added.

About RedHill Biopharma Ltd.

Since its inception in 2009, Redhill Biopharma primarily focuses on the treatment of gastrointestinal and other infectious diseases. The company’s products are based on several technology platforms and are known to be more affordable than other chemical entities under development.

Source credits –

https://www.prnewswire.com/news-releases/redhill-biopharma-annonce-les-resultats-positifs-de-la-phase-2-de-l-etude-covid-19-sur-l-opaganib-en-termes-de-securite-et-d-efficacite-845306278.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

BMW Group to opt for green steel in vehicle production from 2025

BMW Group to opt for green steel in vehicle production from 2025

By Nikita Chaurasia

As climatic changes and other environmental issues take center stage, the BMW Group, to minimize carbon dioxide (CO2) emissions at the core of its supply chain, has reportedly agreed to use green steel from Swedish firm H2 Green Steel beginning in 20...

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

Apple unveils 16-inch MacBook Pro with high-performance M1 processors

By Nikita Chaurasia

Tech giant Apple, Inc. has recently unveiled the 16-inch MacBook Pro, which promises extraordinary design and performance. The model can be customized with the all-new M1 Pro and M1 Max processors.    These new 10-core processors are ...

Kedrion Biopharma expands to North America with Prometic acquisition

Kedrion Biopharma expands to North America with Prometic acquisition

By Nikita Chaurasia

Prometic Life Sciences has developed the first FDA-approved treatment for Congenital Plasminogen Deficiency. This acquisition will enable easy access to advanced therapies for patients suffering from this rare disease. Kedrion Biopharma Inc. has...

Facebook Pages to reduce focus on Likes and followers for Indian users

Facebook Pages to reduce focus on Likes and followers for Indian users

By Nikita Chaurasia

Facebook Inc. has reportedly removed Likes from Facebook Pages for its Indian users to make the platform more user-friendly and easier to understand. This redesign of Facebook Pages was launched in January 2021 and has been rolled out for Indian user...

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

Merchant commerce platform Pine Labs eyeing USD 1 Bn Nasdaq listing

By Nikita Chaurasia

India is likely to witness a record number of IPOs this year, with several companies eyeing public listing to raise funds if the market sentiment remains positive. One such company, Pine Labs is reportedly planning to list itself on Nasdaq by October...